Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
J. R. Merchan
No relevant relationships to disclose
H. C. Pitot
No relevant relationships to disclose
R. Qin
No relevant relationships to disclose
G. Liu
No relevant relationships to disclose
T. R. Fitch
No relevant relationships to disclose
W. J. Maples
No relevant relationships to disclose
J. Picus
Consultant or Advisory Role - Genentech
Research Funding - Wyeth
C. Erlichman
No relevant relationships to disclose